Noradrenergic Add-on Therapy with Extended-Release Guanfacine in Alzheimer’s Disease (NorAD): study protocol for a randomised clinical trial and COVID-19 amendments

Noradrenergic Add-on Therapy with Extended-Release Guanfacine in Alzheimer’s Disease (NorAD): study protocol for a randomised clinical trial and COVID-19 amendments

Abstract Background Guanfacine is a α2A adrenergic receptor agonist approved for treating attention deficit hyperactivity disorder (ADHD). It is thought to act via postsynaptic receptors in the prefrontal cortex, modulating executive functions including the regulation of attention. Attention is affe...

Full description

Bibliographic Details
Main Authors: Karen Hoang, Hilary Watt, Mara Golemme, Richard J. Perry, Craig Ritchie, Danielle Wilson, James Pickett, Chris Fox, Robert Howard, Paresh A. Malhotra
Format: Article
Language:English
Published: BMC 2022-08-01
Series:Trials
Subjects:
Alzheimer’s disease
Guanfacine
Add-on therapy
COVID-19
Online Access:https://doi.org/10.1186/s13063-022-06190-3

Internet

https://doi.org/10.1186/s13063-022-06190-3

Similar Items